EVALUATION OF SIV EXPRESSING IGIF

表达 IGIF 的 SIV 的评估

• 批准号: 7562418
• 负责人: Luis David Giavedoni
• 金额: $ 4.85万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562418
• 关键词: Attenuated; Attenuated Live Virus Vaccine; B-Lymphocytes; Computer Retrieval of Information on Scientific Projects Database; Effector Cell; Evaluation; Funding; Grant; IL18 gene; Immune response; Immune system; Infection; Infection prevention; Institution; Interleukin-18; Life; Link; Macaca mulatta; Natural Killer Cells; Recombinants; Research; Research Personnel; Resources; SIV; SIV Vaccines; Source; United States National Institutes of Health; Viral; Virulence; in vivo

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Interleukin-18 (IL-18, interferon-gamma inducing factor [IGIF]) represents a functional link between effector cells of the innate (phagocytic and NK cells) and adaptive (T- and B-lymphocytes) immune systems. Expression of IL-18 by a live-attenuated SIV vaccine may reduce viral virulence and induce a Type-1 immune response that may prevent infection with pathogenic SIV. The objective of this study was to evaluate the in vivo effects of the infection of rhesus macaques with a recombinant SIV?nef that expresses the rhesus IL18 gene and its potential use as a live-attenuated vaccine (SIVIL18).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 Interleukin-18（IL-18，干扰素-γ诱导因子 [IGIF]）代表先天（吞噬细胞和 NK 细胞）和适应性（T 淋巴细胞和 B 淋巴细胞）免疫系统的效应细胞之间的功能联系。 减毒活 SIV 疫苗表达 IL-18 可降低病毒毒力并诱导 1 型免疫反应，从而预防致病性 SIV 感染。 本研究的目的是评估表达恒河猴 IL18 基因的重组 SIVnef 感染恒河猴的体内效果及其作为减毒活疫苗 (SIVIL18) 的潜在用途。